Beyond Air, Inc. (XAIR)
NASDAQ: XAIR · Real-Time Price · USD
2.290
-0.030 (-1.29%)
Aug 15, 2025, 2:56 PM - Market open

Company Description

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.

It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.

It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home.

In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder.

It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions.

The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019.

Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Beyond Air, Inc.
Beyond Air logo
CountryUnited States
Founded2011
IndustryMedical Devices
SectorHealthcare
Employees61
CEOSteven Lisi

Contact Details

Address:
900 Stewart Avenue, Suite 301
Garden City, New York 11530
United States
Phone516 665 8200
Websitebeyondair.net

Stock Details

Ticker SymbolXAIR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code0001641631
CUSIP Number08862L202
ISIN NumberUS08862L2025
Employer ID47-3812456
SIC Code3841

Key Executives

NamePosition
Amir AvnielChief Executive Officer of NeuroNOS
Steven Adam LisiChief Executive Officer and Chairman of the Board
Douglas Quinton LarsonChief Financial Officer
Michael A. GaulChief Operating Officer
Dr. Andrew R. Colin M.D.Senior Medical Director Global Clinical Leadership and Member of Scientific Advisory Board
David R. WebsterChief Commercial Officer
Dr. John Jett Ph.D.Head of Research and Clinical Development
Adam NewmanCorporate Secretary

Latest SEC Filings

DateTypeTitle
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 12, 202510-QQuarterly Report
Jul 10, 20258-KCurrent Report
Jun 25, 20258-KCurrent Report
Jun 20, 202510-KAnnual Report
Jun 18, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 5, 2025DEF 14AOther definitive proxy statements
Apr 25, 2025PRE 14AOther preliminary proxy statements
Mar 28, 20258-KCurrent Report